Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca.  In addition to joining Absci’s Board, Sir Pangalos will co-chair Absci’s Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas “Mene” Pangalos to its Board of Directors and as co-chair of Absci’s Scientific Advisory Board.

潘加洛斯爵士是一位杰出的生物制药高管，曾领导阿斯利康的生物制药研发。除了加入Absci的董事会之外，潘加洛斯爵士还将担任Absci科学顾问委员会的联合主席。温哥华，华盛顿，2024年1月10日（环球通讯社）--Absci（Nasdaq:ABSI）是一家生成性人工智能药物生产公司，今天宣布任命经验丰富的研发执行教授Menelas“Mene”Pangalos爵士为其董事会成员，并任Absci科学顾问委员会联合主席。

Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. “The rapid evolution of AI in healthcare is unlocking unprecedented opportunities,” said Sir Pangalos. “Absci’s innovative approach in integrating AI with drug discovery is poised to significantly enhance the development of novel therapeutics, and I am excited to contribute to this transformative journey.” With over 25 years of experience in drug discovery and development, Sir Pangalos was instrumental in elevating productivity and scientific excellence at AstraZeneca.

潘加洛斯爵士是阿斯利康生物制药研发部的执行副总裁。随着Absci扩大其合作和全资资产的人工智能投资组合，他加入了Absci。Pangalos爵士表示：“人工智能在医疗保健领域的快速发展正在释放前所未有的机遇。”。“Absci将人工智能与药物发现相结合的创新方法有望显着促进新疗法的发展，我很高兴为这一变革之旅做出贡献。”凭借25年的药物发现和开发经验，潘加洛斯爵士在阿斯利康提高生产力和科学卓越性方面发挥了重要作用。

His tenure there is marked by substantial advancements in R&D productivity, the fostering of key scientific collaborations, and the spearheading of innovative research initiatives that resulted in the company’s drug success rate from pre-clinical studies to completion of Phase III clinical trials increasing from 4% to 19% over a five-year period.

他的任期标志着研发生产力的实质性进步，关键科学合作的促进，以及创新研究举措的引领，导致该公司从临床前研究到完成III期临床试验的药物成功率在五年内从4%上升到19%。

An internationally acclaimed expert in neuroscience and drug development, Sir Pangalos has authored more than 150 peer-reviewed scientific publications. His contributions to UK science earned him a knighthood from Her Majesty The Queen of the United Kingdom of Great Britain and Northern Ir.

潘加洛斯爵士是国际知名的神经科学和药物开发专家，他撰写了150多篇同行评审的科学出版物。他对英国科学的贡献为他赢得了大不列颠及北爱尔兰联合王国女王陛下的爵士头衔。